Kenvue (KVUE) Earnings Date & Reports

Kenvue delivered robust fiscal first quarter results ended March 29, 2026. Net sales rose 4.5% year-over-year to $3.909 billion from $3.741 billion, exceeding analyst consensus of $3.84 billion. This growth included a 3.8% foreign currency tailwind and 0.7% organic sales increase, fueled by 1.0% higher pricing partially offset by 0.3% lower volumes.

GAAP diluted EPS climbed 47% to $0.25 from $0.17, while adjusted diluted EPS surged 33% to $0.32 versus $0.24, topping estimates of $0.27. Gross profit margin expanded 90 basis points to 58.9% on a GAAP basis and 80 basis points to 60.8% adjusted, thanks to supply chain productivity and favorable mix. Adjusted operating margin improved to 24.0% from 19.8%.

By segment, Skin Health and Beauty led with 8.4% sales growth (5.0% organic), followed by Essential Health at 4.9% (1.5% organic) and Self Care at 1.9% (-2.3% organic). Net income totaled $474 million, up from $322 million. No updated guidance was issued due to the pending merger, but management highlighted progress on restructuring and transformation initiatives.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

Following the May 7 release before market open, KVUE shares closed at $17.75, up about 0.4% from the prior day, with elevated volume of over 17 million shares. After-hours trading saw minor dips to $17.73, reflecting a muted response despite the earnings beat. Investor sentiment appears cautiously positive, buoyed by margin expansion and cash flow strength, but tempered by the lack of guidance and merger overhang. Analysts maintain a neutral stance on average, with a $19.58 target suggesting modest upside.

Forward Outlook and Key Factors to Monitor

With no formal guidance due to the pending acquisition by Kimberly-Clark—expected in the second half of 2026—investors should focus on operational momentum from Q1. The merger, approved by shareholders in January, awaits foreign regulatory nods and could bring supply chain synergies and enhanced distribution for brands like Tylenol, Neutrogena, and Listerine.

Key to watch: progress on the 2026 Restructuring Initiative, targeting $250 million in pre-tax costs, which drove much of the margin gains via supply chain optimization and SG&A reductions. Ongoing macro risks like inflation and tariffs may pressure volumes, but pricing power and productivity should support gross margins around 60% adjusted.

Segment dynamics matter—Skin Health and Beauty's volume rebound signals stabilization, while Self Care faces headwinds from allergy seasonality. Cash generation remains robust at $489 million in operating cash flow; debt stands at $8.7 billion against $1.1 billion in cash. The next earnings for Q2 (expected August) may provide merger updates, alongside dividend continuity at a 4.7% yield.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.